Lishmanov Iu B, Maslov L N, Arbuzov A G, Krylatov A V, Platonov A A, Burkova V N, Kaiumova E A
Eksp Klin Farmakol. 2008 May-Jun;71(3):15-22.
We have studied the new complex plant adaptogen preparation tonizid containing dry extracts of Aralia mandshurica, Panax ginseng, Rhodiola rosea, and Eleutherococcus senticosus. The course administration (5 days) of tonizid led to a decrease in the ratio of necrotic zone size/risk area during a 45-min local ischemia and a 2-hr reperfusion in artificially ventilated chloralose anaesthetized rats. This compound decreased the necrotic zone but did not change the size of the risk area. Tonizid also prevented an appearance of ventricular fibrillation during a 45-min coronary artery occlusion, but did not affect the incidence of ventricular arrhythmias during a brief ischemia and reperfusion. In a separate series of experiments, tonizid was administered during 5 days to rats with postinfarction cardiac sclerosis, which was formed 45 days after coronary artery occlusion. In this case, tonizid dose-dependently elevated the ventricular fibrillation threshold. The experiments in vitro were performed on a model of 35-min total ischemia and 30-min reperfusion of isolated rat heart using the Langendorff technique. The course administration of tonizid attenuated the reperfusion-induced decrease in the left ventricular pressure and the rate of contraction. However, tonizid did not prevent a reperfusion-induced reduction in the heart rate, a decrease in the rate of relaxation, and an increase in the final diastolic pressure. Tonizid decreased the creatine kinase levels in the venous effluent from isolated rat heart during reperfusion. At the same time, the plant adaptogen did not affect the incidence of ventricular arrhythmias and coronary flow. It is suggested that tonizid can be used as an adaptogen drug attenuating the contractility dysfunction and preventing an appearance of irreversible cardiomyocyte damage during ischemia and reperfusion. Tonizid exhibits cardioprotective and antifibrillatory properties during acute cardiac ischemia/reperfusion and postinfarction cardiac fibrosis.
我们研究了一种新型复方植物适应原制剂托尼齐德（Tonizid），其含有东北刺人参、人参、红景天和刺五加的干燥提取物。在人工通气的氯醛糖麻醉大鼠中，托尼齐德连续给药5天，可使局部缺血45分钟及再灌注2小时期间坏死区大小与危险区面积之比降低。该化合物减小了坏死区，但未改变危险区的大小。托尼齐德还可预防冠状动脉闭塞45分钟期间室颤的出现，但不影响短暂缺血和再灌注期间室性心律失常的发生率。在另一系列实验中，对冠状动脉闭塞45天后形成心肌梗死后心脏硬化的大鼠连续5天给予托尼齐德。在这种情况下，托尼齐德剂量依赖性地提高了室颤阈值。体外实验采用Langendorff技术，以离体大鼠心脏全心缺血35分钟及再灌注30分钟为模型。托尼齐德连续给药可减轻再灌注诱导的左心室压力和收缩速率降低。然而，托尼齐德未能预防再灌注诱导的心率降低、舒张速率减慢和终末舒张压升高。托尼齐德可降低再灌注期间离体大鼠心脏静脉流出液中的肌酸激酶水平。同时，该植物适应原不影响室性心律失常的发生率和冠状动脉血流量。提示托尼齐德可作为一种适应原药物，减轻收缩功能障碍，预防缺血和再灌注期间不可逆性心肌细胞损伤的出现。托尼齐德在急性心脏缺血/再灌注和心肌梗死后心脏纤维化过程中具有心脏保护和抗纤颤特性。
